2021 World Conference on Lung Cancer (Posters)-FP04. RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

FP04. RATIONALE-307: Updated Biomarker Analysis of Phase 3 Study of Tislelizumab Plus Chemo vs Chemo Alone For 1L Advanced Sq-NSCLC

Back to course

Video Transcription

Video Summary

Zhijie Wang presented an updated biomarker analysis of Rational 307, a phase 3 study of T-selizomib plus chemotherapy versus chemotherapy alone for first-line advanced squamous non-small cell lung cancer. The analysis evaluated biomarkers including PD-L1 expression, tumor mutation burden (TMB), and tumor inflammation signature (TIS). The results showed that T-selizomib plus chemotherapy provided a significantly prolonged progression-free survival (PFS) compared to chemotherapy alone, regardless of PD-L1 expression, tissue TMB, and blood TMB status. Additionally, the TIS score was significantly associated with PFS benefit, highlighting the importance of the tumor microenvironment in the clinical benefit of combination treatment.

Asset Subtitle

Jie Wang

Meta Tag

Speaker Jie Wang

Topic Immunotherapy (Phase II/III Trials)

Keywords

Zhijie Wang

biomarker analysis

Rational 307

T-selizomib

chemotherapy